Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZBIO vs ALMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBIO Captures Overall Composite Edge (49.4 HOLD vs 43.3 HOLD), While ALMS Leads 3–2 on Growth & Valuation Pillars

ZBIO Overall Winner 6-Pillar Tally: ZBIO 2 – 3 ALMS (1 Tie) Matrix Metrics: ZBIO 5 – 2 ALMS

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (49.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. ZBIO trades at $27.93 (N/M Forward P/E, -2747.5% operating margin) versus ALMS at $5.14 (N/M Forward P/E, -5744.5% operating margin).

  • Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.16β · 59% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile ALMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZBIO vs ALMS
ZBIO NASDAQ Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48
ALMS NASDAQ
Alumis Inc. Common Stock
Pharmaceutical Preparations
$5.14
-8.21% 1D
Market Cap $793.4M
TTM Revenue $7.4M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 20.0 Fund 51.0 Flow 67.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -45.8%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $6.43 · SMA50: $7.12

6-Pillar Scorecard Institutional Category Breakdown (ZBIO 2 – 3 ALMS)

Columns: Metric · ZBIO · ALMS
1. Valuation Multiples ALMS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 103.6x
2. Growth & Scale ALMS
Revenue Growth (YoY) -100.0% -37.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $7.4M
Market Cap $1.9B $793.4M
3. Profitability & Quality ALMS
Gross Margin N/A 100.0%
Operating Margin -2747.5% -5744.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -265.1% -93.7%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) -$273M -$352M
Cash Flow Margin N/A N/A
Net Cash / Leverage $177M Net Cash $27M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 95.3% (12th %ile) 68.4% (6th %ile)
Put/Call OI Skew N/A 4433.18x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZBIO (5) vs ALMS (2)
Institutional Metric ZBIO ALMS Criterion Row Edge
Market Capitalization
Scale
$1.9B $793.4M Larger Scale ZBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -37.7% Higher Growth ALMS
Operating Margin (TTM)
Profitability
-2747.5% -5744.5% Higher Margin ZBIO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-265.1% -93.7% Higher ROE ALMS
52-Week Range Position
Momentum
46% ($14–$45) 2% ($5–$31) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 2.24β · 86% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$11M $7.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 103.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$273M ($177M Net Cash) -$352M ($27M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +28.45 pp
ZBIO: +12.44% · ALMS: -16.01%
3M Horizon ZBIO +66.87 pp
ZBIO: -12.47% · ALMS: -79.34%
6M Horizon ZBIO +140.87 pp
ZBIO: +65.17% · ALMS: -75.7%
1Y Horizon ALMS +19.03 pp
ZBIO: -21.68% · ALMS: -2.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ZBIO Revenue ALMS Revenue ZBIO Op. Margin ALMS Op. Margin Margin Leader
FY2023 $50M N/A -74.3% N/A ZBIO
FY2024 $10M N/A -3277.8% N/A ZBIO
FY2025 $10M $20M -3830.6% -1886.9% ALMS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 95.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALMS BREAKDOWN
91d in phase · OBV NEUTRAL
Current IV 68.4%
IV Percentile 6th %ile
Put/Call OI Skew 4433.18x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ALMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ALMS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $793.4M market capitalization and -5744.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZBIO vs ALMS Key Questions & Quantitative Answers

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (49.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. ZBIO trades at $27.93 (N/M Forward P/E, -2747.5% operating margin) versus ALMS at $5.14 (N/M Forward P/E, -5744.5% operating margin). Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.16β · 59% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile ALMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ALMS leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with ALMS at -37.7% YoY revenue growth and +0.0% YoY earnings growth on $7.4M TTM revenue (100.0% gross margin, -5744.5% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), ZBIO cumulative revenue shifted -80.0% while ALMS shifted N/A. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ALMS.

ALMS screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus ALMS (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, ALMS carries 68.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 4433.18x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.